Company

Have you ever wished for a younger, healthier body? I certainly have.

At Abrax Japan, we are pioneering a groundbreaking technology to stimulate various skin-derived factors. This innovative approach aims to harness the untapped potential of the human immune system to achieve a healthier body from the inside out.

In recent years, significant advancements have been made in the development of both prescription and cosmetic drugs. However, many diseases still lack effective treatments, or current treatments come with undesirable side effects. Our strategy is both novel and safe because it utilizes natural substances produced by our own skin. We believe that this treatment will create a healthier skin environment by extracting lipids from the blood and delivering them to the skin surface. Additionally, this technology may stimulate weight loss, providing a comprehensive approach to health and wellness. This unique approach targets skin diseases and lipid disorders, addressing a significant unmet need in the medical community.

At Abrax, we have leveraged findings that challenge the conventional understanding of skin-derived factors. Our commitment is to develop and manufacture drugs based on this innovative concept, aiming to create treatment strategies that are not only effective but also user-friendly for patients.

CEO, Abrax Japan

Jo NARITA

Growing up, I have always wanted to work in the field of medicine and to take care of people with disease. After being mesmerized by research experiences during my training, I dreamed of helping patients not only through direct care but also through my research.

Now, I am doing exactly that; I am a physician scientist and wear two hats: one as a medical doctor and another as a scientist. I believe that my role as a physician scientist is to bridge basic science and clinical medicine. In essence, physician scientists help to transition “bench to bedside”. Accordingly, a life-long goal of mine has been to help patients through the translation of basic science discovery into therapeutics or diagnostics in a clinically meaningful manner. As such, my research interests have been focused on intracellular signaling pathways that could be therapeutically targeted to alter the function and development of immune cells, which could potentially provide benefit to disease outcome.

In our work investigating the interactions of the immune system with the skin microenvironment, we found that a cytokine (i.e., an immune hormone) known as thymic stromal lymphopoietin (TSLP) is a critical regulator of sebum production and skin barrier function. Sebum is a lipid-rich substance that protects our skin from the environment. In some diseases such as eczema , sebum secretion is reduced and in others such as acne vulgaris, sebum is overproduced. Thus, control of sebum secretion in either direction is beneficial for treatment of these diseases.

In addition, being an energy-rich substance, sebum secretion can also have an impact on whole body lipid metabolism. Taking advantage of this newly discovered axis, we established Abrax Japan to translate our findings into practical human use for the treatment of skin and lipid disorders. Here at Abrax, we strive to promote health through the skin by this novel concept.

Abrax Japan CSA

Taku KAMBAYASHI